Our Mission
At Next Phase Analytix, our mission is to provide cutting-edge analytical solutions for controlled release products from a molecular standpoint. We empower innovators, enhance product development, and help your team get to the next phase. We help early-stage and translational biotech teams move faster by providing data collection, analysis, and strategic advice services in an agile manner without the lab overhead. With deep analytical expertise and strategic support, we help you translate complex experiments into clear actions.
Services
Empowering biotech innovation through cutting-edge data analysis and interpretation for lipid nanoparticles, small molecules, and complex materials. Our expertise and capabilities span a range of methods, including but not limited to HPLC (SEC-MALS), cryo-TEM, SEM, DSC/TGA, FTIR, PXRD, flow cytometry and AFM/STM.
Data & Analysis
Providing top-tier experimental data generation and insightful interpretation services for precise characterization of various biotechnological materials.
Knowledge Transfer
Enabling knowledge transfer and experimental design support to enhance R&D processes, IND-enabling studies, and training programs increasing team capabilities.
Strategy Consulting
Offering analytical strategy development tailored to your needs, ensuring efficient and effective pathways for research and development.
About
Markrete Krikorian is the founder and principal at Next Phase Analytix, a consultancy that helps early-stage and translational biotech companies get the right data efficiently so they can make critical decisions with confidence. With an MIT PhD and over 15 years of experience across academia and industry, spanning nucleic acid therapeutics, polymers, small molecules, and advanced delivery systems, she’s known for turning complex datasets into clear, actionable insights.
Markrete built her career solving high-stakes formulation and analytical challenges, from developing patentable technologies to leading cross-platform characterization strategies. At Next Phase Analytics, she brings that same agile, data-driven approach to help biotech teams de-risk development, accelerate timelines, and move from discovery to decision with speed, clarity, and precision.
